
CLAIMS

1. ~~A method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of~~ Use of a LINE-1 inhibitor, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating or preventing a disease in a subject, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,



or .

2. The use ~~method~~ of claim 1, wherein the disease is ataxia-telangiectasia.

3. The use ~~method~~ of claim 1, wherein the disease is age-related macular degeneration.

4. The use ~~method~~ of claim 1, wherein the disease is systemic lupus erythematosus.

5. The use ~~method~~ of claim 1, wherein the disease is IFN-associated autoimmune disease.

6. The use ~~method~~ of claim 5, wherein the disease is psoriasis.

7. The use ~~method~~ of claim 1, wherein the disease is Fanconi Anemia.

8. The use ~~method~~ of claim 1, wherein the disease is idiopathic pulmonary fibrosis.

9. The use ~~method~~ of claim 1, wherein the disease is cardiovascular disease.


~~10. The method of any one of claims 1-9, wherein the LINE-1 inhibitor is islatravir, censavudine, or elvucitabine.~~

~~11. The method of any one of claims 1-10, wherein the LINE-1 inhibitor is islatravir.~~

~~12. The method of claim 11, wherein about 0.1 mg to about 10 mg of islatravir is orally administered to the subject per day.~~

10 ~~13~~. The use ~~method~~ of any one of claims 1-9 ~~claims 1-10~~, wherein the LINE-1 inhibitor is censavudine.

11. The use of any one of claims 1-9, wherein the LINE-1 inhibitor is:



.

~~14. The method of any one of claims 1-10, wherein the LINE-1 inhibitor is elvucitabine.~~

~~15. The method of any one of claims 1-10, wherein the LINE-1 inhibitor is a compound of Table 1.~~

~~16. The method of any one of claims 1-10, wherein the LINE-1 inhibitor is a compound of Table 2.~~

12 ~~17~~. The use ~~method~~ of any one of claims 1-11 ~~claims 1-16~~ for treating the disease.


13 ~~18~~. The use ~~method~~ of any one of claims 1-11 ~~claims 1-16~~ for preventing the disease.

14 ~~19~~. The use ~~method~~ of any one of claims 1-13 ~~claims 1-18~~, further comprising administering one or more optional therapeutic agents to the subject.

~~20. The method of any one of claims 1-19, wherein the subject is a human.~~

15 ~~21~~. The use ~~method~~ of any one of claims 1-14 ~~claims 1-20~~, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.

16 ~~22~~. A kit comprising a LINE-1 inhibitor, or a pharmaceutical composition thereof, and instructions of administering the LINE-1 inhibitor, or pharmaceutical composition thereof, to a subject having a disease, wherein the disease is ataxia-telangiectasia, ~~and the systemic disease is~~ age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,




~~23. The kit of claim 22, wherein the LINE-1 inhibitor is islatravir censavudine, or elvucitabine.~~

~~24. The kit of claim 23, wherein the LINE-1 inhibitor is islatravir.~~

17 ~~25~~. The kit of claim 16 ~~claim 23~~, wherein the LINE-1 inhibitor is censavudine.

18. The kit of claim 16, wherein the LINE-1 inhibitor is:



~~26. The kit of claim 23, wherein the LINE-1 inhibitor is elvucitabine.~~

~~27. The kit of claim 22, wherein the LINE-1 inhibitor is a compound of Table 1.~~

~~28. The kit of claim 22, wherein the LINE-1 inhibitor is a compound of Table 2.~~

19 ~~29~~. The kit of any one of claims 16-18 ~~claims 22-28~~ further comprising one or more optional therapeutic agents.

20 ~~30~~. The kit of any one of claims 16-19 ~~claims 22-29~~, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.